The new man at the helm of Eli Lilly has started off his time as the US pharma major’s chief executive by announcing a series of organizational and leadership structure changes. 6 January 2017
David-Alexandre “DA” Gros has joined Neurocrine Biosciences as president and chief operating officer, the American biotech group announced today. 6 January 2017
Biotech firm Sobi have announced the recruitment of Armin Reininger as senior vice president and head of global medical and scientific affairs. 5 January 2017
US-based biotech firm Gilead has recruited Alessandro Riva as senior vice president of hematology and oncology. Dr Riva helped develop more than 20 cancer compounds as head of oncology at Swiss giant Novartis, including both targeted and immune-oncology treatments. 4 January 2017
Ireland-headquartered Shire has announced the appointment of Ian Clark as a non-executive director of the company with effect from today (January 3). 3 January 2017
Provectus Biopharmaceuticals has said that, on December 27, 2016, its board of directors unanimously voted to terminate Peter Culpepper, effective immediately, from all positions held with the company, including chief executive and chief operating officer. 30 December 2016
US fertility treatment specialist OvaScience lost nearly a third of its value after it announced major workforce cuts and the departure of two top executives. 22 December 2016
News that AstraZeneca was losing the experienced head of one its focus areas caused a slight share price wobble on Monday – but the company is confident that his shoes will be ably filled. 21 December 2016
US biotech major Biogen has now selected a new chief executive to replace outgoing incumbent George Scangos, who has led the company since 2010 but announced his intention to leave last year, from its own ranks. 20 December 2016
Genentech, the US-based biotech unit of Swiss pharma giant Roche, has announced its new chief executive after the retirement of Ian Clark. 16 December 2016
Troubled Valeant Pharmaceuticals has announced the departure of three executives, as the business continues to restructure at the close of a punishing 2016. 14 December 2016
Shares of US biotech firm Alexion Pharmaceuticals plunged as much as 15.6% to $111.44 on Monday, after it was revealed that its chief executive David Hallal had resigned for personal reasons, and chief financial officer Vikas Sinha was leaving to pursue other opportunities. 13 December 2016
Effective February 1, 2017, Robert LaCaze will become executive vice president of the new Oncology Strategic Business unit at the Pharmaceuticals Division of German pharma major Bayer. 13 December 2016
A new man is at the helm of the European Federation of Pharmaceutical Industries and Association (EFPIA) after the departure of Richard Bergström. 12 December 2016
French pharma company Ipsen today announced that Claude Bertrand, executive vice president, R&D, chief scientific officer, will depart Ipsen on January, 2017, to join another company. 12 December 2016
Lisa Anson, president of AstraZeneca UK and Ireland, has been elected as the next president of trade group the Association of the British Pharmaceutical Industry (ABPI). 7 December 2016
Israel’s Teva Pharmaceutical Industries says that Dipankar Bhattacharjee has been appointed president and chief executive, Global Generic Medicines Group, effective Monday. 6 December 2016
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024